Figure 2 | Scientific Reports

Figure 2

From: Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins

Figure 2

Tolerogenic lipid particles prevents immunogenicity of several antigens in an antigen-specific manner. (a) General immunization protocol—oral pre-exposure of antigens in the presence and absence of Lyso-PS nanoparticles, followed by re-challenge with free antigens. (b) Tolerogenic lipid particles utilizing Lyso-PS nanoparticles, but not PS ones, induced oral tolerance towards FVIII in HA mice following four weekly re-challenge with 0.4 μg free FVIII, and OVA (c) in Swiss Webster mice following four weekly re-challenge with 2 μg free OVA. (d) Immunization protocol for antigen specificity study. (e) Total anti-GAA antibodies after four weekly re-challenges with 1 μg free GAA. (f) Total anti-OVA IgG1 concentration after four weekly re-challenges with 1 μg free OVA. All data are represented as mean ± SEM. Statistical significance was denoted by P < 0.05 (*) by a one-way ANOVA test followed by Tukey’s post-hoc analysis on log-transformed data.

Back to article page